We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+11.34%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$713M
AUM Growth
-$55M
Cap. Flow
-$96.6M
Cap. Flow %
-13.55%
Top 10 Hldgs %
96.7%
Holding
19
New
2
Increased
3
Reduced
–
Closed
5

Top Buys

Rank Stock Value
1
KIDS icon
OrthoPediatrics
KIDS
+$7.25M
2
AKBA icon
Akebia Therapeutics
AKBA
+$5.6M
3
GKOS icon
Glaukos
GKOS
+$4.65M
4
DERM
Dermira, Inc.
DERM
+$1.66M
5
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$133K

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$41.6M
2
FLXN
Flexion Therapeutics, Inc.
FLXN
+$36.3M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$18.4M
4
KALV
KalVista Pharmaceuticals
KALV
+$18.3M
5
APEN
Apollo Endosurgery, Inc.
APEN
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 91.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$167M
$423M 59.25%
3,549,320
– –
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$65.9M 9.24%
1,553,937
– –
DERM
3
DELISTED
Dermira, Inc.
DERM
$55.2M 7.74%
1,984,364
+62,784
+3% +$1.66M
CRVS icon
4
Corvus Pharmaceuticals
CRVS
$1.1B
$33.6M 4.71%
3,244,046
– –
AKBA icon
5
Akebia Therapeutics
AKBA
$327M
$33.1M 4.64%
2,225,000
+337,465
+18% +$5.6M
MRUS
6
DELISTED
Merus
MRUS
$27.4M 3.84%
1,410,417
– –
NBRV
7
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$17.5M 2.45%
11,699
+84
+0.7% +$133K
RARX
8
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$17.3M 2.42%
2,031,562
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$8.79M 1.23%
740,740
– –
IVTY
10
DELISTED
Invuity, Inc
IVTY
$8.46M 1.19%
1,363,848
– –
KIDS icon
11
OrthoPediatrics
KIDS
$485M
$7.27M 1.02%
+379,014
New +$7.25M
WMGIZ
12
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
CRSP icon
13
CRISPR Therapeutics
CRSP
$4.58B
$5.24M 0.74%
223,317
– –
GKOS icon
14
Glaukos
GKOS
$9.02B
$4.01M 0.56%
+156,429
New +$4.65M
ANAB icon
15
AnaptysBio
ANAB
$1.6B
– –
-1,190,604
Closed -$41.6M
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
– –
-2,725,283
Closed -$18.3M
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-592,794
Closed -$18.4M
APEN
18
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-274,472
Closed -$1.28M
FLXN
19
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-1,500,000
Closed -$36.3M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q4 2017 Portfolio in Review

As of Q4 2017, Novo Holdings A/S held 19 positions worth $713M, down 7.2% from $768M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Novo Holdings A/S withdrew a net $96.6M in Q4 2017, closing 5 positions. Its most notable exit was AnaptysBio, an estimated $41.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in OrthoPediatrics worth $7.27M.

  • Novo Holdings A/S's largest Q4 2017 buy was OrthoPediatrics: 379,014 shares worth $7.27M.
  • Novo Holdings A/S added most to Akebia Therapeutics in Q4 2017, an estimated $5.6M increase.
  • Novo Holdings A/S fully exited AnaptysBio in Q4 2017, selling an estimated $41.6M.
  • Novo Holdings A/S's ten largest holdings make up 97% of its $713M portfolio in Q4 2017.
  • Novo Holdings A/S opened 2 new positions and closed 5 in Q4 2017.
  • Novo Holdings A/S's portfolio value fell 7.2% quarter-over-quarter to $713M.

Based on Novo Holdings A/S's 13F filing for Q4 2017, filed 14 Feb 2018.